Breaking News Instant updates and real-time market news.

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13

G1 presents additional data from randomized Phase 2 trial in first-line SCLC

G1 Therapeutics announced data from new analyses of its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for the treatment of first-line small cell lung cancer. The analyses demonstrated clinically meaningful improvements for neutrophil, red blood cell and lymphocyte measures in patients treated with trilaciclib compared to placebo. With regard to lymphocytes, trilaciclib preserved or improved B cell and T cell subset counts, including activated CD8+ cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios in peripheral blood compared to placebo. The company reported topline data from this trial in March 2018 showing robust myelopreservation benefits of trilaciclib. Consistent with previously reported results, new analyses demonstrated that trilaciclib reduced clinically relevant consequences of chemotherapy-induced myelosuppression versus placebo. Overall, there were fewer greater than or equal to Grade 3 treatment emergent adverse events with trilaciclib compared to placebo, mostly due to lower number of greater than or equal to Grade 3 hematologic TEAEs.

  • 27

    Nov

GTHX G1 Therapeutics
$46.88

-0.07 (-0.15%)

09/18/18
NEED
09/18/18
NO CHANGE
Target $76
NEED
Buy
G1 Therapeutics price target raised to $76 from $60 at Needham
Needham analyst Chad Messer raised his price target on G1 Therapeutics to $76 and kept his Buy rating, citing the company's announcement yesterday of amended phase 2 trial protocol for trilaciclib testing in combination with chemotherapy and Tecentrq. The analyst believes that the myelopreservation data from this trial "may help bolster the available dataset" that the company is planning to bring to the FDA in the first half of 2019 for discussion regarding a viable path to approval. Messer adds that he looks forward to the "updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October".
09/17/18
HCWC
09/17/18
NO CHANGE
Target $79
HCWC
Buy
G1 Therapeutics price target raised to $79 from $61 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for G1 Therapeutics to $79 saying the company, in his opinion, makes positive revision to its Phase 2 protocol in newly diagnosed small cell lung cancer patients. The analyst views the earlier availability of comprehensive myelopreservation data as a positive that could add substantially to discussions with regulators in early 2019. Following the announcement of the revised protocol, White has increased confidence in the approval of trilaciclib. He keeps a Buy rating on G1 Therapeutics.
09/10/18
BTIG
09/10/18
INITIATION
Target $80
BTIG
Buy
G1 Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company's "unique" position of potentially developing two "best in class" CDK4/6 inhibitors - trilaciclib and lerociclib. The analyst notes that trilaciclib's positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, "significant upside" in the stock price remains thanks to the "large market opportunity" of both programs that he estimates to be around $2B by 2025.
05/29/18
HCWC
05/29/18
INITIATION
Target $61
HCWC
Buy
G1 Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started G1 Therapeutics with a Buy rating and $61 price target. The company's trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression, White tells investors in a research note. He believes investors are missing the potential of trilaciclib, which he thinks become part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, that receive chemotherapy.

TODAY'S FREE FLY STORIES

03:05
09/18/19
09/18
03:05
09/18/19
03:05
General news
FX Update: The dollar majors have been holding narrow ranges »

FX Update: The dollar…

03:00
09/18/19
09/18
03:00
09/18/19
03:00
General news
FX Update: The dollar majors have been holding narrow ranges »

FX Update: The dollar…

01:50
09/18/19
09/18
01:50
09/18/19
01:50
General news
FX Action: »

FX Action: The USD is…

01:45
09/18/19
09/18
01:45
09/18/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
FOMC preview: »

FOMC preview: a quarter…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
Fed SEP forecasts: t »

Fed SEP forecasts: the…

TBIO

Translate Bio

$11.01

0.405 (3.82%)

21:06
09/17/19
09/17
21:06
09/17/19
21:06
Syndicate
Translate Bio 9M share Spot Secondary priced at $10.00 »

Citi, Jefferies and SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SWK

Stanley Black & Decker

$144.45

0.73 (0.51%)

21:05
09/17/19
09/17
21:05
09/17/19
21:05
Downgrade
Stanley Black & Decker rating change at KeyBanc »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LEN

Lennar

$53.10

-0.23 (-0.43%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Lennar rating change at KeyBanc »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

WHR

Whirlpool

$152.15

3.4 (2.29%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Whirlpool rating change at KeyBanc »

Whirlpool downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.